Indole-3-propionic acid promotes hepatic stellate cells inactivation

Mariana Ilha, Ratika Sehgal, Johanna Matilainen, Kirsi Rilla, Dorota Kamińska, S.p. Gandhi, Ville Männistö, Charlotte Ling, Stefano Romeo, Päivi Pajukanta, Eija Pirinen, Kirsi A. Virtanen, Kirsi H. Pietiläinen, Maija Vaittinen, Jussi PihlajamäkiJournal of Translational Medicine 2025 · DOI

TL;DR

This study reveals that indole-3-propionic acid (IPA), a gut-derived metabolite, can promote the inactivation of hepatic stellate cells (HSCs) by inducing apoptosis and altering mitochondrial function. These findings suggest IPA holds therapeutic potential for treating liver fibrosis, a condition linked to HSC activation.

What Problem Does This Paper Address?

Liver fibrosis, a significant consequence of metabolic dysfunction-associated fatty liver disease (MASLD), is characterized by the excessive accumulation of extracellular matrix by activated hepatic stellate cells (HSCs). While HSCs can be cleared through apoptosis or inactivation during fibrosis reversal, the precise mechanisms driving this process, particularly those influenced by gut microbiota metabolites, remain incompletely understood. Previous research has indicated lower serum IPA levels in individuals with liver fibrosis, hinting at a potential protective role for this metabolite. This paper aims to explore the association between serum IPA levels and liver gene expression, investigate IPA's effects on HSC inactivation in vitro, and elucidate the underlying molecular mechanisms.

Methods

The researchers employed a multi-pronged approach:

  • Human Liver Transcriptomics and Epigenomics: They analyzed liver tissue from obese individuals undergoing bariatric surgery. RNA sequencing was used to assess gene expression, and DNA methylation was analyzed using the Infinium HumanMethylation450 BeadChip. This allowed them to correlate serum IPA levels with global and mitochondrial-related gene expression, as well as DNA methylation patterns.
  • In Vitro HSC Model: The human hepatic stellate cell line LX-2 was used to study the direct effects of IPA.
  • Apoptosis Assays: Flow cytometry (Annexin V/7-AAD staining) was used to quantify viable, necrotic, early, and late apoptotic cells.
  • Mitochondrial Respiration Analysis: The Seahorse Extracellular Flux Analyzer was employed to measure oxygen consumption rate (OCR) and extracellular acidification rates (ECAR), providing insights into cellular energy metabolism.
  • Mitochondrial Morphology and Dynamics: Mitotracker Red CMXRos staining and confocal microscopy were used to visualize mitochondrial networks, while transmission electron microscopy (TEM) provided ultrastructural details.
  • Gene Expression Analysis: Quantitative RT-PCR was used to measure the mRNA levels of specific genes involved in fibrogenesis, apoptosis, survival, and mitochondrial dynamics.

Datasets

The study utilized:

  • Human Liver Tissue: Samples from 116 obese individuals without type 2 diabetes (T2D) from the Kuopio Obesity Surgery (KOBS) study.
  • LX-2 Cell Line: A well-established human hepatic stellate cell line for in vitro experiments.

No new benchmarks were introduced; standard techniques were applied to analyze existing datasets.

Key Insights and Ideas

  • Gut-Microbiome-Liver Axis: This study reinforces the critical link between gut microbial metabolites (like IPA) and liver health, suggesting a direct influence on cellular processes relevant to fibrosis.
  • IPA as a Modulator of HSC Fate: IPA appears to be a key player in shifting HSCs from an activated, pro-fibrotic state towards inactivation, offering a potential therapeutic avenue.
  • Mitochondrial Bioenergetics as a Target: IPA's impact on mitochondrial respiration and morphology highlights the central role of cellular energy metabolism in HSC activation and inactivation.
  • Apoptosis as a Primary Mechanism: The induction of apoptosis in HSCs by IPA is a significant finding, as apoptosis is a crucial mechanism for clearing activated HSCs and resolving fibrosis.

Key Results

  • IPA and Gene Expression: Serum IPA levels were associated with the expression of liver genes enriched in apoptosis, mitophagy, and longevity pathways. AKT1 and YKT6 emerged as key overlapping genes in these analyses.
  • IPA Induces HSC Apoptosis: IPA treatment (specifically at 1 mM) significantly increased late apoptosis and the overall apoptosis rate in LX-2 cells, even in the presence of TGF-β1 (a known HSC activator).
  • IPA Impairs Mitochondrial Respiration: 1 mM IPA treatment decreased oxygen consumption rate (OCR) parameters, including basal and maximal respiration, proton leak, and ATP production, leading to a less energetic profile in LX-2 cells.
  • IPA Alters Mitochondrial Morphology: IPA treatment modulated mitochondrial shape and size, shifting them from spherical towards intermediate morphology, and affected mitochondrial network complexity.
  • IPA Modulates Gene Expression: IPA treatment altered the expression of genes related to fibrogenesis (decreasing COL1A2, MMP2), apoptosis (increasing CASP8), and survival (increasing BCL-2, TIMP1, NF-kB subunits), suggesting a complex regulatory role.

Limitations and Future Work

The authors acknowledge several limitations:

  • Exclusion of T2D Patients: The study excluded patients with T2D to isolate IPA's effects, which limits the broader applicability of findings to individuals with advanced liver disease and T2D.
  • Supraphysiological IPA Concentration: The 1 mM IPA concentration used in in vitro experiments, while non-toxic and effective for inducing apoptosis, is higher than physiological serum concentrations (1-10 μM). Further research is needed to determine the effective dose and broader metabolic fate of IPA.
  • Liver Tissue vs. HSCs: The association of serum IPA with liver transcriptomics and DNA methylation was derived from whole liver tissue, not solely HSCs. While LX-2 cells were used for in vitro studies, future work could benefit from co-culture systems involving hepatocytes, HSCs, and immune cells.
  • Mechanistic Elucidation: While IPA's effects on apoptosis, mitochondrial function, and gene expression are demonstrated, the precise molecular mechanisms and interactions with other hepatic cell types require further investigation.

Future studies are recommended to explore IPA's pharmacokinetics and pharmacodynamics, its potential as a mitochondrial uncoupler in HSCs, and its detailed interactions with other cell types in the liver microenvironment.

Summary updated

Abstract

In conclusion, these data support that IPA has a plausible therapeutic effect and may induce apoptosis and the HSC phenotype towards the inactivation state, extending the possibilities to suppress hepatic fibrogenesis by interfering with HSC activation and mitochondrial metabolism.
BibTeX
@article{ilha2025indole,
  author = {Mariana Ilha and Ratika Sehgal and Johanna Matilainen and Kirsi Rilla and Dorota Kamińska and S.P. Gandhi and Ville Männistö and Charlotte Ling and Stefano Romeo and Päivi Pajukanta and Eija Pirinen and Kirsi A. Virtanen and Kirsi H. Pietiläinen and Maija Vaittinen and Jussi Pihlajamäki},
  title = {{Indole-3-propionic acid promotes hepatic stellate cells inactivation}},
  journal = {Journal of Translational Medicine},
  year = {2025},
  doi = {10.1186/s12967-025-06266-z},
}
Figure